Exposure to PCE, TCE, Vinyl Chloride, or Benzene and Peripheral Artery Disease Risk
Based on emerging evidence, trichloroethylene (TCE) exposure appears to increase cardiovascular disease risk through mechanisms that could contribute to peripheral artery disease development, though direct causal evidence specifically linking these industrial solvents to PAD remains limited.
Current Evidence Assessment
The 2024 ACC/AHA PAD guidelines 1 and 2011 ESC PAD guidelines 2 comprehensively address traditional PAD risk factors (smoking, diabetes, hypertension, dyslipidemia) but do not mention occupational or environmental exposures to PCE, TCE, vinyl chloride, or benzene as established risk factors for peripheral artery disease. This absence from major guidelines indicates these exposures are not currently recognized as clinically significant PAD risk factors in standard practice.
Emerging Research Findings
Trichloroethylene (TCE)
Recent research suggests TCE may pose cardiovascular risks through specific mechanisms:
- A 2021 study demonstrated that TCE-exposed workers had significantly elevated methylated arginine biomarkers (ADMA, SDMA, L-NMMA) compared to controls 3
- These methylated arginines inhibit nitric oxide synthesis, a known pathway for cardiovascular disease development
- The strongest correlation was between ADMA levels and trichloroacetic acid (TCE metabolite) (r = 0.453, p < 0.01) 3
- However, this study assessed general cardiovascular risk markers, not PAD specifically
Perfluorooctane Sulfonate (PFOS) - Related Compound
A 2026 Mendelian randomization study found that genetically predicted PFOS exposure was associated with increased PAD risk 4. While PFOS is not one of the queried compounds (PCE, TCE, vinyl chloride, benzene), this represents the only study in the provided evidence directly linking an industrial chemical exposure to PAD. The study identified PPAR and PI3K-Akt signaling pathways and immune microenvironment remodeling as potential mechanisms 4.
Perchloroethylene (PCE) and Vinyl Chloride
The provided evidence addresses exposure assessment and monitoring 5, 6 but does not establish any link to PAD or cardiovascular outcomes. These studies confirm environmental and occupational exposures occur but provide no outcome data.
Benzene
No evidence was provided regarding benzene and PAD.
Clinical Interpretation
The absence of these exposures from authoritative PAD guidelines 1, 2 reflects the lack of sufficient epidemiological evidence to establish them as recognized PAD risk factors. While mechanistic plausibility exists for TCE through endothelial dysfunction pathways 3, and emerging genetic evidence suggests PFOS-PAD associations 4, these findings:
- Are preliminary and require validation in larger epidemiological studies
- Do not yet meet the threshold for clinical practice guideline inclusion
- Should not currently alter standard PAD risk assessment or screening protocols
Practical Approach
When evaluating patients with occupational exposures to these solvents:
- Focus on established PAD risk factors identified in guidelines: smoking history, diabetes, hypertension, and dyslipidemia 1, 2
- Document occupational exposure history as part of comprehensive assessment
- Apply standard PAD screening (ankle-brachial index) based on traditional risk factors, not solvent exposure alone
- Consider that workers in industries using these solvents often have concurrent smoking exposure, which is the dominant modifiable PAD risk factor 2
In summary, current clinical practice should not treat PCE, TCE, vinyl chloride, or benzene exposure as established PAD risk factors, though emerging research warrants continued surveillance of exposed populations.